These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 30932880)

  • 1. Sub-terahertz vibrational spectroscopy of ovarian cancer and normal control tissue for molecular diagnostic technology.
    Globus T; Moskaluk C; Pramoonjago P; Gelmont B; Moyer A; Bykhovski A; Ferrance J
    Cancer Biomark; 2019; 24(4):405-419. PubMed ID: 30932880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
    Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
    BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 5. Engrailed-2 (EN2) - a novel biomarker in epithelial ovarian cancer.
    McGrath SE; Annels N; Madhuri TK; Tailor A; Butler-Manuel SA; Morgan R; Pandha H; Michael A
    BMC Cancer; 2018 Oct; 18(1):943. PubMed ID: 30285763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features.
    Zuberi M; Mir R; Das J; Ahmad I; Javid J; Yadav P; Masroor M; Ahmad S; Ray PC; Saxena A
    Clin Transl Oncol; 2015 Oct; 17(10):779-87. PubMed ID: 26063644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
    Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
    Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The biphasic expression pattern of miR-200a and E-cadherin in epithelial ovarian cancer and its correlation with clinicopathological features.
    Xu S; Xu P; Wu W; Ou Y; Xu J; Zhang G; Li J; Xu G
    Curr Pharm Des; 2014; 20(11):1888-95. PubMed ID: 23888941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of multiple myeloma SET domain (MMSET) is associated with advanced tumor aggressiveness and poor prognosis in serous ovarian carcinoma.
    Yang S; Zhang Y; Meng F; Liu Y; Xia B; Xiao M; Xu Y; Ning X; Li H; Lou G
    Biomarkers; 2013 May; 18(3):257-63. PubMed ID: 23566000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
    Ramalingam P
    Oncology (Williston Park); 2016 Feb; 30(2):166-76. PubMed ID: 26892153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of an immune gene-set based Prognostic signature in ovarian cancer.
    Shen S; Wang G; Zhang R; Zhao Y; Yu H; Wei Y; Chen F
    EBioMedicine; 2019 Feb; 40():318-326. PubMed ID: 30594555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of miRNA-21, -103, -129, -150 in serous ovarian cancer.
    Wilczyński M; Żytko E; Danielska J; Szymańska B; Dzieniecka M; Nowak M; Malinowski J; Owczarek D; Wilczyński JR
    Arch Gynecol Obstet; 2018 Mar; 297(3):741-748. PubMed ID: 29335784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The conglomeration of diagnostic, prognostic and therapeutic potential of serum miR-199a and its association with clinicopathological features in epithelial ovarian cancer.
    Zuberi M; Khan I; Gandhi G; Ray PC; Saxena A
    Tumour Biol; 2016 Aug; 37(8):11259-66. PubMed ID: 26951510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five Hypermethylated MicroRNA Genes as Potential Markers of Ovarian Cancer.
    Braga EA; Loginov VI; Burdennyi AM; Filippova EA; Pronina IV; Kurevlev SV; Kazubskaya TP; Kushlinskii DN; Utkin DO; Ermilova VD; Kushlinskii NE
    Bull Exp Biol Med; 2018 Jan; 164(3):351-355. PubMed ID: 29313235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of EphB6 in ovarian serous carcinoma is associated with grade, TNM stage and survival.
    Gu Y; Li F; Qian N; Chen X; Wang H; Wang J
    J Clin Pathol; 2016 May; 69(5):448-53. PubMed ID: 26468391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stromal alterations in ovarian cancers via wavelength dependent Second Harmonic Generation microscopy and optical scattering.
    Tilbury KB; Campbell KR; Eliceiri KW; Salih SM; Patankar M; Campagnola PJ
    BMC Cancer; 2017 Feb; 17(1):102. PubMed ID: 28166758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A proteomic signature of ovarian cancer tumor fluid identified by highthroughput and verified by targeted proteomics.
    Poersch A; Grassi ML; Carvalho VP; Lanfredi GP; Palma CS; Greene LJ; de Sousa CB; Carrara HHA; Candido Dos Reis FJ; Faça VM
    J Proteomics; 2016 Aug; 145():226-236. PubMed ID: 27222041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating Cell-Free miR-373, miR-200a, miR-200b and miR-200c in Patients with Epithelial Ovarian Cancer.
    Meng X; Müller V; Milde-Langosch K; Trillsch F; Pantel K; Schwarzenbach H
    Adv Exp Med Biol; 2016; 924():3-8. PubMed ID: 27753009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
    Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
    J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy.
    Santin AD; Zhan F; Bellone S; Palmieri M; Cane S; Bignotti E; Anfossi S; Gokden M; Dunn D; Roman JJ; O'Brien TJ; Tian E; Cannon MJ; Shaughnessy J; Pecorelli S
    Int J Cancer; 2004 Oct; 112(1):14-25. PubMed ID: 15305371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.